Yousif Capital Management LLC Has $3.69 Million Stake in BioMarin Pharmaceutical Inc. $BMRN

Yousif Capital Management LLC trimmed its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.5% in the second quarter, HoldingsChannel reports. The firm owned 67,040 shares of the biotechnology company’s stock after selling 1,021 shares during the period. Yousif Capital Management LLC’s holdings in BioMarin Pharmaceutical were worth $3,685,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMRN. V Square Quantitative Management LLC acquired a new stake in BioMarin Pharmaceutical during the 2nd quarter valued at $25,000. Farther Finance Advisors LLC increased its holdings in BioMarin Pharmaceutical by 95.9% during the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 211 shares in the last quarter. Rise Advisors LLC acquired a new stake in BioMarin Pharmaceutical during the 1st quarter valued at $30,000. Brooklyn Investment Group increased its holdings in BioMarin Pharmaceutical by 2,250.0% during the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 540 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new stake in BioMarin Pharmaceutical during the 1st quarter valued at $71,000. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Stock Up 1.2%

NASDAQ:BMRN opened at $53.09 on Thursday. BioMarin Pharmaceutical Inc. has a 12-month low of $51.56 and a 12-month high of $73.51. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $10.19 billion, a P/E ratio of 15.75, a P/E/G ratio of 0.73 and a beta of 0.33. The stock’s fifty day simple moving average is $55.87 and its 200-day simple moving average is $57.79.

Analyst Ratings Changes

A number of research analysts have commented on BMRN shares. HC Wainwright started coverage on BioMarin Pharmaceutical in a research report on Monday, September 8th. They issued a “neutral” rating and a $60.00 price objective on the stock. Wall Street Zen lowered BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 11th. Morgan Stanley decreased their price objective on BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 22nd. Wedbush reiterated an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. Finally, Raymond James Financial started coverage on BioMarin Pharmaceutical in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $85.00 price objective on the stock. Thirteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $93.26.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.